PENHOET EDWARD 4
4 · IMMUNE DESIGN CORP. · Filed Apr 4, 2019
Insider Transaction Report
Form 4
PENHOET EDWARD
Director10% Owner
Transactions
- Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−4,281→ 0 totalExercise: $1.23→ Common Stock (4,281 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−12,500→ 0 totalExercise: $1.31→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−10,000→ 0 totalExercise: $5.60→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−12,500→ 0 totalExercise: $4.05→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−3,058→ 0 totalExercise: $1.48→ Common Stock (3,058 underlying)
Footnotes (2)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding.
- [F2]Not Applicable.